
Core Scientific has surged 57.3% in the past year on the back of a long-term AI infrastructure agreement with AMD, but valuation metrics suggest the stock is already expensive. Trading at about 15.0× price-to-sales—roughly double peer average and four times the software industry average—the stock appears to price in much of the AI growth story already, leaving little margin of safety for investors.
Summaries like this, in your inbox every morning.
Sign up free →What happened
Core Scientific shares have returned 57.3% over the past 12 months. The company has secured a long-term AI infrastructure agreement with AMD, which the article says may support future revenue expectations.
Why it matters
Despite the strong stock performance, Core Scientific trades at about 15.0× price-to-sales (P/S), roughly 2× the peer average of 7.4× and more than 4× the wider software industry average of 3.6×. The article estimates a fair P/S ratio at around 8.1×, suggesting the stock is currently overvalued on this framework. Heavy data center spending ahead of fully secured customer contracts also increases execution risk.
What to watch
The key question is whether Core Scientific's share price already reflects the AI and data center growth story, or still leaves room for a margin of safety. The company scores undervalued on 0 of 6 valuation checks tracked, leaning expensive rather than offering a clear bargain on broader metrics.
Core Scientific has delivered strong shareholder returns, gaining 57.3% over the past 12 months. The company's growth narrative centers on a long-term AI infrastructure agreement with AMD, which provides visibility into future revenue streams as demand for data center capacity for artificial intelligence workloads continues to rise.
However, a detailed valuation analysis reveals the stock is trading well above historical norms and peer benchmarks. Core Scientific currently trades at about 15.0× price-to-sales (P/S)—a metric chosen because revenue is the company's main positive financial anchor while free cash flow and earnings are still loss-making. This 15.0× multiple is roughly 2× the peer average of 7.4× and more than 4× the wider software industry average of 3.6×. Based on the company's risk profile and business mix, the estimated fair P/S ratio is around 8.1×, which sits closer to peer multiples but below the current market price. This gap suggests the shares are overvalued on this framework.
The valuation puzzle raises a critical question: does the current stock price already reflect the AI and data center growth story, or is there still room for reasonable margin of safety? Core Scientific scores undervalued on 0 of 6 valuation checks tracked, meaning it leans expensive rather than offering a clear bargain on the broader metrics. An additional execution risk shadows the bullish narrative: the company is undertaking heavy data center spending ahead of fully secured customer contracts. This timing mismatch can increase execution risk and pressure on returns if customer demand or deal timelines shift. For investors weighing the current price, the fundamental question is whether the AMD agreement and long-term AI infrastructure tailwinds justify a premium that is already 2× peers and 4× the software industry average.
Core Scientific's 57.3% return over the past year reflects growing investor confidence in AI infrastructure plays. The long-term AMD deal represents a concrete commitment to the company's data center expansion strategy, providing visibility into future revenue. However, the article's valuation analysis reveals a disconnect between market price and fundamental metrics. At 15.0× P/S, the stock commands a significant premium: it trades at roughly double the average for comparable peer companies and more than four times the broader software industry median. This suggests that much of the upside from the AMD agreement and the broader AI infrastructure narrative is already reflected in the current share price. The article flags a specific risk: heavy data center spending ahead of fully secured customer contracts. This spending creates execution risk—the company is committing capital to infrastructure buildout before all revenue is contractually locked in, which could pressure returns if customer demand or deal timing does not materialize as expected. For investors evaluating entry points, the valuation framework points to limited margin of safety at current levels.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
No comments yet. Be the first to share your thoughts!
Log in to join the discussion





Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started FreeFree · takes 30 seconds · unsubscribe anytime